BASKING RIDGE, N.J., May 10, 2013 /PRNewswire/ -- In recognition of Food Allergy Awareness Week, Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced their participation as the national presenting sponsor of the Food Allergy Research & Education (FARE) Walk for Food Allergy. With an estimated one in 13 children in the U.S. living with a food allergy, a considerable increase from previously reported figures, the walks bring together communities across the country to raise funds for important food allergy research, education, advocacy and awareness.
"Mylan Specialty is honored to support the FARE Walk for Food Allergy for the seventh consecutive year," said Heather Bresch , CEO of Mylan Inc. "We remain committed to those with potentially life-threatening or severe allergies, and given the growing incidence of food allergies, it's important that we continue to raise awareness to ensure that everyone is prepared to manage a life-threatening allergic reaction. The FARE Walk for Food Allergy aims to accomplish just that, by joining people together in a way that inspires others, motivates change and drives conversation about this significant public health issue."
Food allergies are a common cause of anaphylaxis, a life-threatening allergic reaction. The most common food allergens include peanuts, tree nuts, shellfish, fish, dairy, soy, eggs and wheat. People with severe allergies should have an anaphylaxis action plan in place, which includes avoiding known allergens, recognizing symptoms, having access to two epinephrine auto-injectors at all times and seeking immediate emergency medical care should anaphylaxis occur.
"The FARE Walk for Food Allergy is one of our flagship programs, and we are pleased to again have Mylan Specialty on board as our presenting sponsor," said John L. Lehr , Chief Executive Officer of FARE. "This year, with more than 65 walks planned nationwide, the Walk program continues to raise critical funds for food allergy education programs, advocacy initiatives and research, and to bring together thousands of Americans to increase awareness and understanding of the life-altering and potentially life-threatening nature of food allergies."
For more information or to register for the FARE Walk for Food Allergy, visit www.foodallergywalk.org.
Anaphylaxis is a life-threatening allergic reaction that has many possible triggers, occurs quickly, without warning, and must be treated immediately with epinephrine. Symptoms may include hives or redness of the skin, tightness in the throat, nausea, dizziness, breathing problems, a decrease in blood pressure and/or fainting. Anaphylaxis can be caused by triggers such as food, stinging and biting insects, medicines, latex or even exercise. Epinephrine is the only first-line treatment for anaphylaxis. According to the food allergy guidelines developed by the National Institute of Allergy and Infectious Diseases, if experiencing anaphylaxis, a person should use an epinephrine auto-injector and seek immediate emergency medical attention. Epinephrine is a naturally-occurring hormone, also known as adrenaline, and it should be available at all times to patients at risk. Delays in epinephrine administration have been associated with negative health consequences, even possibly death.
About Mylan Specialty
Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions and psychiatric disorders. For more information, please visit www.mylanspecialty.com.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
© 2013 Mylan Specialty L.P. All rights reserved.
|SOURCE Mylan Specialty L.P.|
Copyright©2012 PR Newswire.
All rights reserved